Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksOrchid Pharma locked at upper circuit on USFDA nod

    Orchid Pharma locked at upper circuit on USFDA nod

    The company has received ANDA approval from USFDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

    Moneycontrol News
    May 15, 2019 / 09:37 IST

    Shares of Orchid Pharma locked at upper circuit on May 15 on the back of USFDA nod for Risedronate Sodium Tablets.

    At 09:24 hrs Orchid Pharma was quoting at Rs 4, up Rs 0.17, or 4.44 percent.

    There were pending buy orders of 33,257 shares, with no sellers available.

    The company has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

    Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

    orchid

    For more market news, click here

    Moneycontrol News
    first published: May 15, 2019 09:36 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347